MetaVia is trading 5.14% down now at $1.66, with no credible company-specific catalyst identified.
- No credible September 11, 2026 company-specific announcement, earnings release, analyst downgrade, or regulatory catalyst was identified.
- Recent coverage references September 9 preclinical DA-1726 findings and an analyst maintaining a Buy rating; neither directly explains the September 11 decline.
- Broader markets are rising, so the move is not confirmed as market-driven.